Replies to post #223591 on Biotech Values

[biotech_researcher]

GILD needs to do something...

“It's also 7th late-stage pipeline failure in recent yrs outside core anti-viral competence.”

$GILD Selonsertib failure hardly a shock after the weak Ph2 they ran

It's also 7th late-stage pipeline failure in recent yrs outside core anti-viral competence:
JAKi momelotinib
Anti-MMP9 Andecaliximab
Anti-LOXL2 Simtuzumab
Idelalisib(safety/commercial flop)
Eleclazine
Enoximone pic.twitter.com/FWBmMB8LOF

— Andy Biotech (@AndyBiotech) February 11, 2019